Exelixis
Presence
Exelixis is one of the...
Exelixis is a company listed under the stock ticker EXEL (US).
Executives
View the org chart displaying its 27 main executives
Most searched biographies at Exelixis
- Michael Morrissey, Director, Chief Executive Officer and President
- Bob Oliver, Director
- Jack Wyszomierski, Director
Popular executive movements at Exelixis
- Gail Eckhard has joined the company as Director (posted on January 8 2024).
- Mary Beckerle has joined the company as Director (posted on January 8 2024).
- Amy Peterson has joined the company as Executive Vice President, Product Development & Medical Affairs and Chief Medical Officer (posted on August 24 2023).
Create your alert
to follow the executive moves at Exelixis.
Biotechnology
Exelixis has 2,277 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and Adaptive Phage Therapeutics (United States (USA)).
Popular M&A news in Biotechnology
- Histogen has filed for bankruptcy protection (posted on April 19 2024).
- Bruker has announced the acquisition of NanoString Technologies (posted on April 18 2024).
- Vertex Pharmaceuticals has announced the acquisition of Alpine Immune Sciences (posted on April 16 2024).
Popular contacts in Biotechnology
News
Press releases by Exelixis
- Exelixis to Release Second Quarter 2022 Financial Results on Tuesday, August 9, 2022 | Exelixis, Inc.
- Exelixis Announces Cabozantinib in Combination with Nivolumab and Ipilimumab Significantly Improved Progression-Free Survival in Phase 3 COSMIC-313 Pivotal Trial in Patients with Previously Untreated Advanced Kidney Cancer | Exelixis, Inc.
- Exelixis and Ryvu Therapeutics Establish Exclusive License Agreement to Develop Novel STING Agonist-Based Targeted Cancer Therapies | Exelixis, Inc.
- Exelixis to Webcast Fireside Chat as Part of the William Blair Biotech Focus Conference | Exelixis, Inc.
- Exelixis Announces Initiation of the STELLAR-303 Phase 3 Pivotal Trial Evaluating XL092 in Patients with Metastatic Colorectal Cancer | Exelixis, Inc.
- Exelixis and BioInvent Establish Exclusive Option and License Agreement to Develop Novel Antibody-Based Immuno-Oncology Therapies | Exelixis, Inc.
- Exelixis To Webcast Fireside Chats as Part of Investor Conferences in June | Exelixis, Inc.
- Exelixis Announces Detailed Results from Urothelial Carcinoma and Non-Small Cell Lung Cancer Cohorts of the COSMIC-021 Trial at ASCO 2022 | Exelixis, Inc.
- Exelixis Announces Results from Phase 2 Trial of Cabozantinib in Combination with Pembrolizumab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma at ASCO 2022 | Exelixis, Inc.
- Exelixis Announces First Quarter 2022 Financial Results and Provides Corporate Update | Exelixis, Inc.
- View more press releases Close
Social media about Exelixis
- Exelixis on Wikipedia, Google News & Yahoo Finance
- Exelixis on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Michael Morrissey 
